Naprelan 2021 U.S. PROMOTIONAL AUDIT REPORT

Published July 2022 • 33 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Naprelan through reportable promotional activity in 2021 and how does this compare to its peer set in the Ankylosing Spondylitis, Bursitis, Gout, Osteoarthritis, Rheumatoid Arthritis, and Tendonitis markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Alvogen’s depth of coverage vary within key specialties (e.g., Nursing, Physician Assistant, Neurology, Anesthesiology, Pain Medicine, Family Medicine, Internal Medicine, and Physical Medicine and Rehabilitation) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Naprelan throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Naprelan in 2021?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
• Over 7,240 paid interactions across 3,450 physicians made on behalf of Naprelan were carefully examined to support our analysis. In addition, interaction data from 25 peer products (e.g. Actemra, Avsola, Cimzia, Cosentyx, Duexis, Enbrel, Humira, Ilaris, Inflectra, Kevzara, Kineret, Krystexxa, Mitigare, Olumiant, Orencia, Pennsaid, Rayos, Remicade, Renflexis, Rinvoq, Rituxan, Simponi, Taltz, Xeljanz, and Zilretta ) was leveraged to provide benchmarking and market insights.